BioFinlandin jäsen

Labsystems Diagnostics Oy (LDx), Finland has been a forerunner in innovative diagnostic research and development for the last 40 years. The company develops, manufactures and markets high quality enzyme immunoassays, molecular assays and Point-of-Care tests.

As an established European company, LDx has committed itself to developing high quality diagnostics products for use in clinical and research laboratories, for consumer use and as OEM products. A highly rigorous quality system and CE-marked products ensure sustainable quality of the products.

Within 40 years of experience, throughout different ownerships, LDx has been a key pioneer to achieve many milestones. LDx is well known for its world’s first revolutionary microplate ELISA reader - The Multiskan, which was developed and launched in the global markets back in 1978. The company was one of the first in the world to develop EIA tests on microplate format, as well as to create a peptide based HIV assay.

The first fluorometric PKU test for Newborn Screening on microplate was developed by the company. In the Point-of-Care field discipline, the company was the first to launch Troponin I test, patented Celiac test and Chlamydia pneumoniae IgM test. The fully automated high throughput system and LC-MS tests for Newborn Screening are the most recent milestones.